Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MBRX | US
-0.06
-2.48%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.36
2.43
2.52
2.36
Moleculin Biotech Inc. a clinical stage pharmaceutical company focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors as well as pancreatic cancer and other malignancies. It is also developing WP1220 an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston Texas.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
61.7%1 month
96.6%3 months
102.2%6 months
88.8%-
-
0.39
0.03
0.02
0.52
-
-
-27.60M
6.71M
6.71M
-
-
-
-
-86.82
4.17
6.23
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.33
Range1M
0.79
Range3M
2.59
Rel. volume
0.30
Price X volume
31.39K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.64 | 7.34M | -1.20% | n/a | 0.00% |
TFFP | TFFP | Biotechnology | 2.06 | 7.14M | -1.44% | n/a | 1.26% |
Portage Biotech Inc | PRTG | Biotechnology | 6.71 | 7.04M | 0.15% | 0.27 | 1.47% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.18 | 6.55M | 1.95% | n/a | 0.89% |
Aptose Biosciences Inc | APTO | Biotechnology | 0.36 | 6.52M | -2.17% | n/a | -37.59% |
CDIO | CDIO | Biotechnology | 0.2113 | 6.47M | -7.49% | n/a | 28.31% |
Adial Pharmaceuticals Inc | ADIL | Biotechnology | 0.9701 | 6.21M | -5.82% | n/a | 0.00% |
Hoth Therapeutics Inc | HOTH | Biotechnology | 0.9 | 6.21M | -3.26% | n/a | 0.44% |
Molecular Templates Inc | MTEM | Biotechnology | 0.93 | 6.16M | 186.07% | n/a | 155.07% |
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.052 | 6.14M | -13.33% | n/a | 461.91% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.52 | 0.53 | Par |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 0.39 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 102.25 | 72.92 | Riskier |
Debt to Equity | 0.03 | -1.24 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 6.71M | 3.78B | Emerging |